NCT05596045View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 28, 2022

Primary Completion Date

March 8, 2023

Study Completion Date

October 9, 2023

Conditions
SARS CoV 2 Infection
Interventions
DRUG

ASC10

Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days

DRUG

Placebo

Participants will be randomized to receive placebo

Trial Locations (2)

33012

Aga Clinical Trials, Hialeah

36207

Pinnacle Research Group, Anniston

Sponsors
All Listed Sponsors
lead

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY